← Arbutus Biopharma overview

Arbutus Biopharma vs ACADIA Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Arbutus Biopharma Corp (ABUS)

Q3 2026
▲4

Arbutus turns patent wins into cash and a big share buyback

  • New patent suits against Pfizer and BioNTech Arbutus and partner Genevant sued Pfizer and BioNTech in Canada and Europe over the lipid nanoparticle technology used in their COVID vaccine, seeking injunctions and damages. If Arbutus wins or settles, it could collect royalties or a lump sum, which would lift the stock.

    This is the period's main new legal catalyst that could bring Arbutus more money.

  • Moderna pays $178M; up to $230M to shareholders Arbutus received about $178 million from its $950 million Moderna patent settlement and said it will return up to roughly $230 million to shareholders through buybacks. Real cash in hand and a plan to hand it back supports the share price.

    It shows the patent money is real and being used to reward shareholders.

  • $230M tender offer at $5.00-$5.75 a share Arbutus launched a modified Dutch auction to buy back up to $230 million of stock at $5.00 to $5.75 per share, funded from cash on hand. A buyback at a set price can put a floor under the stock and signals management thinks it is cheap.

    The buyback is the concrete action that moves the share price this period.

  • Buyback final: 46M shares at $5 each Arbutus will cancel about 46 million shares at $5 each, roughly 23% of the company, leaving nearly 153.3 million shares outstanding. Fewer shares means each remaining share owns more of the company, which can raise the value per share.

    It is the completed result of the buyback and changes Arbutus's share count.

August 2026
▲4

Arbutus turns patent wins into cash and a big share buyback

  • New patent suits against Pfizer and BioNTech Arbutus and partner Genevant sued Pfizer and BioNTech in Canada and Europe over the lipid nanoparticle technology used in their COVID vaccine, seeking injunctions and damages. If Arbutus wins or settles, it could collect royalties or a lump sum, which would lift the stock.

    This is the period's main new legal catalyst that could bring Arbutus more money.

  • Moderna pays $178M; up to $230M to shareholders Arbutus received about $178 million from its $950 million Moderna patent settlement and said it will return up to roughly $230 million to shareholders through buybacks. Real cash in hand and a plan to hand it back supports the share price.

    It shows the patent money is real and being used to reward shareholders.

  • $230M tender offer at $5.00-$5.75 a share Arbutus launched a modified Dutch auction to buy back up to $230 million of stock at $5.00 to $5.75 per share, funded from cash on hand. A buyback at a set price can put a floor under the stock and signals management thinks it is cheap.

    The buyback is the concrete action that moves the share price this period.

  • Buyback final: 46M shares at $5 each Arbutus will cancel about 46 million shares at $5 each, roughly 23% of the company, leaving nearly 153.3 million shares outstanding. Fewer shares means each remaining share owns more of the company, which can raise the value per share.

    It is the completed result of the buyback and changes Arbutus's share count.

Latest
▲4

Arbutus turns patent wins into cash and a big share buyback

  • New patent suits against Pfizer and BioNTech Arbutus and partner Genevant sued Pfizer and BioNTech in Canada and Europe over the lipid nanoparticle technology used in their COVID vaccine, seeking injunctions and damages. If Arbutus wins or settles, it could collect royalties or a lump sum, which would lift the stock.

    This is the period's main new legal catalyst that could bring Arbutus more money.

  • Moderna pays $178M; up to $230M to shareholders Arbutus received about $178 million from its $950 million Moderna patent settlement and said it will return up to roughly $230 million to shareholders through buybacks. Real cash in hand and a plan to hand it back supports the share price.

    It shows the patent money is real and being used to reward shareholders.

  • $230M tender offer at $5.00-$5.75 a share Arbutus launched a modified Dutch auction to buy back up to $230 million of stock at $5.00 to $5.75 per share, funded from cash on hand. A buyback at a set price can put a floor under the stock and signals management thinks it is cheap.

    The buyback is the concrete action that moves the share price this period.

  • Buyback final: 46M shares at $5 each Arbutus will cancel about 46 million shares at $5 each, roughly 23% of the company, leaving nearly 153.3 million shares outstanding. Fewer shares means each remaining share owns more of the company, which can raise the value per share.

    It is the completed result of the buyback and changes Arbutus's share count.

ACADIA Pharmaceuticals Inc (ACAD)

Q3 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

August 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

Latest
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.